Price to Earnings (P/E)
since 2005
Calculation
Regeneron Pharmaceuticals Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income (loss)1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | 18.19 | = | 775.06 | ÷ | 42.61 | 42.61 | = | 4,504,900 | ÷ | 105,719,806 | |
| Feb 5, 2025 | 17.76 | = | 716.72 | ÷ | 40.36 | 40.36 | = | 4,412,600 | ÷ | 109,324,682 | |
| Feb 5, 2024 | 25.99 | = | 936.33 | ÷ | 36.02 | 36.02 | = | 3,953,600 | ÷ | 109,761,896 | |
| Feb 6, 2023 | 19.68 | = | 780.86 | ÷ | 39.68 | 39.68 | = | 4,338,400 | ÷ | 109,325,532 | |
| Feb 7, 2022 | 8.37 | = | 622.36 | ÷ | 74.40 | 74.40 | = | 8,075,300 | ÷ | 108,539,282 | |
| Feb 8, 2021 | 15.09 | = | 494.90 | ÷ | 32.79 | 32.79 | = | 3,513,200 | ÷ | 107,131,899 | |
| Feb 7, 2020 | 19.86 | = | 381.87 | ÷ | 19.23 | 19.23 | = | 2,115,800 | ÷ | 110,019,809 | |
| Feb 7, 2019 | 18.17 | = | 406.46 | ÷ | 22.37 | 22.37 | = | 2,444,400 | ÷ | 109,277,189 | |
| Feb 8, 2018 | 28.99 | = | 322.62 | ÷ | 11.13 | 11.13 | = | 1,198,511 | ÷ | 107,696,798 | |
| Feb 9, 2017 | 42.64 | = | 360.00 | ÷ | 8.44 | 8.44 | = | 895,522 | ÷ | 106,080,755 | |
| Feb 11, 2016 | 60.50 | = | 367.24 | ÷ | 6.07 | 6.07 | = | 636,056 | ÷ | 104,788,145 | |
| Feb 12, 2015 | 118.44 | = | 401.74 | ÷ | 3.39 | 3.39 | = | 348,074 | ÷ | 102,616,962 | |
| Feb 13, 2014 | 77.00 | = | 326.98 | ÷ | 4.25 | 4.25 | = | 424,362 | ÷ | 99,928,368 | |
| Feb 15, 2013 | 21.42 | = | 164.93 | ÷ | 7.70 | 7.70 | = | 750,269 | ÷ | 97,450,601 | |
| Feb 21, 2012 | — | = | 99.26 | ÷ | -2.36 | -2.36 | = | -221,760 | ÷ | 93,888,977 | |
| Feb 17, 2011 | — | = | 37.67 | ÷ | -1.16 | -1.16 | = | -104,468 | ÷ | 89,959,044 | |
| Feb 18, 2010 | — | = | 26.66 | ÷ | -0.83 | -0.83 | = | -67,830 | ÷ | 81,653,378 | |
| Feb 26, 2009 | — | = | 15.40 | ÷ | -1.03 | -1.03 | = | -82,710 | ÷ | 79,976,762 | |
| Feb 27, 2008 | — | = | 18.90 | ÷ | -1.34 | -1.34 | = | -105,600 | ÷ | 78,984,745 | |
| Mar 12, 2007 | — | = | 19.04 | ÷ | -1.56 | -1.56 | = | -102,337 | ÷ | 65,630,744 | |
| Feb 28, 2006 | — | = | 16.37 | ÷ | -1.68 | -1.68 | = | -95,446 | ÷ | 56,858,721 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Annual Report.
The price-to-earnings (P/E) ratio exhibits significant fluctuations over the observed period. Initially, the ratio is unavailable due to negative earnings per share (EPS). A notable shift occurs beginning in 2013, with the P/E ratio increasing substantially and remaining elevated for several years before declining and stabilizing.
- Early Period (2006-2012)
- From 2006 through 2012, the company reported negative EPS, resulting in a non-calculable P/E ratio. This indicates a period of unprofitability, preventing meaningful valuation based on earnings.
- Initial Increase (2013-2015)
- The P/E ratio experiences a dramatic increase from 21.42 in 2013 to 118.44 in 2015. This surge coincides with a transition to positive and increasing EPS, suggesting growing investor confidence and a willingness to pay a premium for each dollar of earnings. The ratio peaks in 2015, indicating a potentially overvalued stock or exceptionally high growth expectations.
- Subsequent Decline and Stabilization (2016-2021)
- Following the peak in 2015, the P/E ratio demonstrates a downward trend, decreasing to 15.09 by 2021. While EPS continues to rise during this period, the rate of increase appears to be factored into the stock price, leading to a more moderate valuation. The ratio fluctuates between approximately 15 and 60 during these years.
- Recent Fluctuations (2022-2026)
- The P/E ratio exhibits renewed volatility in the later years of the observation period. It declines to a low of 8.37 in 2022, potentially reflecting concerns about future earnings growth or broader market conditions. A subsequent increase to 25.99 in 2025 suggests a partial recovery in investor sentiment. The most recent value, in 2026, is 17.76, indicating a stabilization around a level similar to that observed in 2017-2019.
Overall, the P/E ratio demonstrates a clear correlation with the company’s earnings performance. The transition from negative to positive EPS is a key driver of the initial increase, while subsequent fluctuations reflect changes in growth expectations and market sentiment. The observed trends suggest a dynamic valuation influenced by both company-specific factors and broader economic conditions.
Comparison to Competitors
Regeneron Pharmaceuticals Inc., P/E, long-term trends, comparison to competitors
| Regeneron Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | 18.19 | 94.06 | 25.81 | 17.30 | 40.93 | 47.45 | 21.54 | 21.66 | 16.79 | 19.83 | 28.82 | 31.58 |
| Feb 5, 2025 | 17.76 | 79.59 | 38.24 | — | 38.12 | 77.63 | 296.57 | 26.92 | 13.49 | 18.42 | 32.03 | — |
| Feb 5, 2024 | 25.99 | 63.84 | 23.14 | 12.27 | 39.09 | 135.24 | 16.17 | 10.73 | 893.99 | 73.42 | 35.65 | 30.42 |
| Feb 6, 2023 | 19.68 | 22.62 | 19.56 | 23.97 | 25.65 | 50.08 | 22.68 | 22.97 | 19.21 | 7.58 | 30.55 | 23.02 |
| Feb 7, 2022 | 8.37 | 22.07 | 21.05 | 20.92 | 29.94 | 40.66 | 12.36 | 20.93 | 14.78 | 11.76 | 27.35 | 26.55 |
| Feb 8, 2021 | 15.09 | 40.17 | 18.82 | — | 44.49 | 31.95 | 641.48 | 28.92 | 26.72 | 19.62 | 27.89 | 20.18 |
| Feb 7, 2020 | 19.86 | 17.82 | 17.07 | 41.99 | 38.34 | 16.19 | 16.45 | 25.99 | 20.60 | 11.63 | 33.36 | 52.90 |
| Feb 7, 2019 | 18.17 | 20.60 | 14.01 | 16.81 | 29.77 | 39.13 | 15.26 | 23.74 | 33.46 | 21.58 | 35.19 | 22.59 |
| Feb 8, 2018 | 28.99 | 35.47 | 64.06 | 103.55 | 27.25 | — | 22.75 | 268.10 | 61.63 | 9.99 | 37.66 | 155.08 |
| Feb 9, 2017 | 42.64 | 16.54 | 16.03 | 20.56 | 23.02 | 32.39 | 6.83 | 20.08 | 46.14 | 28.10 | 30.45 | — |
| Feb 11, 2016 | 60.50 | 17.01 | 15.95 | 64.22 | 17.85 | 33.35 | 6.75 | 18.80 | 31.64 | 26.37 | 26.19 | — |
| Feb 12, 2015 | 118.44 | 55.08 | 22.96 | 49.80 | 23.69 | 33.06 | 12.85 | 17.15 | 13.94 | 23.03 | 27.26 | — |
| Feb 13, 2014 | 77.00 | 19.64 | 18.69 | 35.01 | 19.74 | 13.88 | 42.00 | 18.72 | 37.83 | 9.32 | 38.43 | — |
| Feb 15, 2013 | 21.42 | 11.51 | 15.68 | 30.56 | 17.73 | 14.99 | 25.20 | 19.64 | 20.94 | 13.51 | 22.54 | — |
| Feb 21, 2012 | — | — | 14.61 | 15.07 | 16.92 | 10.42 | 12.20 | 18.48 | 18.63 | 15.99 | 15.58 | 267.42 |
| Feb 17, 2011 | — | — | 10.53 | 13.99 | 18.29 | 7.86 | 10.68 | 12.23 | 116.63 | 18.63 | 20.87 | — |
| Feb 18, 2010 | — | — | 12.10 | 4.03 | 20.93 | 9.18 | 16.29 | 14.22 | 9.00 | 16.41 | 23.49 | — |
| Feb 26, 2009 | — | — | 12.06 | 7.68 | 12.56 | — | 20.29 | 11.67 | 6.53 | 10.25 | 15.25 | — |
| Feb 27, 2008 | — | — | 15.64 | 20.60 | 17.35 | 19.26 | 25.19 | 17.07 | 29.88 | 18.51 | 30.76 | — |
| Mar 12, 2007 | — | — | 25.43 | 34.64 | 19.65 | 22.40 | — | 17.02 | 21.57 | 9.18 | 113.28 | — |
| Feb 28, 2006 | — | — | 23.70 | 14.96 | 21.38 | 31.90 | 34.15 | 16.95 | 16.62 | 23.92 | 25.36 | — |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Regeneron Pharmaceuticals Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Regeneron Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 4, 2026 | 18.19 | 28.98 |
| Feb 5, 2025 | 17.76 | 45.15 |
| Feb 5, 2024 | 25.99 | 32.80 |
| Feb 6, 2023 | 19.68 | 20.23 |
| Feb 7, 2022 | 8.37 | 19.27 |
| Feb 8, 2021 | 15.09 | 34.89 |
| Feb 7, 2020 | 19.86 | 21.03 |
| Feb 7, 2019 | 18.17 | 22.89 |
| Feb 8, 2018 | 28.99 | 35.21 |
| Feb 9, 2017 | 42.64 | 20.62 |
| Feb 11, 2016 | 60.50 | 19.37 |
| Feb 12, 2015 | 118.44 | 21.40 |
| Feb 13, 2014 | 77.00 | 19.54 |
| Feb 15, 2013 | 21.42 | 17.56 |
| Feb 21, 2012 | — | 16.42 |
| Feb 17, 2011 | — | 16.11 |
| Feb 18, 2010 | — | 11.66 |
| Feb 26, 2009 | — | 12.21 |
| Feb 27, 2008 | — | 20.04 |
| Mar 12, 2007 | — | 17.46 |
| Feb 28, 2006 | — | 20.94 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Regeneron Pharmaceuticals Inc., P/E, long-term trends, comparison to industry (health care)
| Regeneron Pharmaceuticals Inc. | Health Care | |
|---|---|---|
| Feb 4, 2026 | 18.19 | 28.31 |
| Feb 5, 2025 | 17.76 | 38.03 |
| Feb 5, 2024 | 25.99 | 30.62 |
| Feb 6, 2023 | 19.68 | 351,256.81 |
| Feb 7, 2022 | 8.37 | 21.55 |
| Feb 8, 2021 | 15.09 | 32.22 |
| Feb 7, 2020 | 19.86 | 22.09 |
| Feb 7, 2019 | 18.17 | 24.32 |
| Feb 8, 2018 | 28.99 | 33.04 |
| Feb 9, 2017 | 42.64 | 21.90 |
| Feb 11, 2016 | 60.50 | 19.53 |
| Feb 12, 2015 | 118.44 | 21.38 |
| Feb 13, 2014 | 77.00 | 18.67 |
| Feb 15, 2013 | 21.42 | 15.77 |
| Feb 21, 2012 | — | 15.79 |
| Feb 17, 2011 | — | 15.12 |
| Feb 18, 2010 | — | 11.71 |
| Feb 26, 2009 | — | 13.07 |
| Feb 27, 2008 | — | 19.29 |
| Mar 12, 2007 | — | 18.61 |
| Feb 28, 2006 | — | 21.71 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).